Welcome to DFWA

Welcome to the
Defence Force Welfare Association (DFWA)


We exist simply to foster the best interests and wellbeing of all members of the Australian Defence Force and their families in any matter likely to affect them during or after their period of service.

Read more about us at ABOUT / BACKGROUND

We are also a member of the Alliance of Defence Service Organisations (ADSO), which comprises many of Australia's major military ex service organisations (ESO). The Alliance represents a significant number of members of Australia's Defence Family on national advocacy and representative matters to the Australian Parliament and all political parties. Its aim is to promote and protect the conditions and well-being of the Defence Family that embraces over three million people.


as a CURRENT NEWS item becomes stale, it is transferred either to "ARCHIVED CURRENT NEWS" or into one of the CURRENT ISSUES (see list at left of page)  

24 September 2018 - VETERANS SUICIDE.  The Australian Institute of Health and Welfare has released two new reports (available on http://www.aihw.gov.au) on this matter.  Further details, including DVA comment, are available at CURRENT ISSUES / HEALTH on the left of this homepage.

14 September 2018 - MILITARY COVENANT.  An update on progress towards the implementation of an Australian Military Covenant, including the latest version of the Covenant, is available under CURRENT ISSUES on the left of the homepage. 

3 September 2018 - MEFLOQUINE.  Following our submission to the Senate inquiry into Mefloquine (see 30 August note below), on 30 August the DFWA National President Kel Ryan, appeared as a witness and fronted the Inquiry.  He opening remarks are here and Stuart McCarthy, the major advocate on this matter, has thanked both the DFWA and Kel Ryan for our efforts.

30 August 2018 – DFWA SUBMISSION TO THE USE OF MEFLOQUINE AND TEFENOQUINE IN THE ADF. The DFWA has made a submission to Parliament’s Joint Standing Committee on Foreign Affairs, Defence and Trade inquiry into the use of mefloquine and tefenoquine in the ADF.  The continuing difficulties with the use of the quinoline anti-malarial drugs mefloquine and tafenoquine by the ADF have not ceased. Mefloquine has been in use now since the early 1990s, while the experimental drug tafenoquine was used in a series of clinical trials during the period 1998- 2001. Despite decades of increasing evidence linking quinoline drugs to acute as well as chronic neurological and psychiatric illnesses, including the risk of suicide in some affected ADF personnel the latter are struggling to receive appropriate and adequate health care.

16 August 2018 - DFWA MEDIA RELEASE - ROYAL COMMISSION.  The Senate yesterday passed a motion that the Hayne Royal Commission into Banking and Superannuation be extended to include the Commonwealth Superannuation Corporation. No longer should the Government be allowed to hide behind the misconception that the Commonwealth Superannuation Corporation (CSC) is held to account through the annual Senate Estimates process. This has been proven wrong time and time again. Fairness and honesty must now take hold. The Terms of Reference of the Banking Royal Commission must be extended to cover the governance of all relevant Commonwealth retirement benefits and superannuation funds. Read our Media Release here

Find us on Facebook